Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Change in Accured Expenses (2016 - 2025)

Aethlon Medical (AEMD) has disclosed Change in Accured Expenses for 15 consecutive years, with $248736.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Change in Accured Expenses rose 1118.7% year-over-year to $248736.0, compared with a TTM value of -$53360.0 through Mar 2025, down 134.06%, and an annual FY2025 reading of -$53360.0, down 134.06% over the prior year.
  • Change in Accured Expenses was $248736.0 for Q1 2025 at Aethlon Medical, up from -$397466.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $540780.0 in Q1 2022 and bottomed at -$397466.0 in Q4 2024.
  • Average Change in Accured Expenses over 5 years is $5254.5, with a median of -$25892.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses tumbled 1435.09% in 2024, then skyrocketed 1118.7% in 2025.
  • Year by year, Change in Accured Expenses stood at -$69219.0 in 2021, then skyrocketed by 540.01% to $304572.0 in 2022, then plummeted by 108.5% to -$25892.0 in 2023, then crashed by 1435.09% to -$397466.0 in 2024, then skyrocketed by 162.58% to $248736.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for AEMD at $248736.0 in Q1 2025, -$397466.0 in Q4 2024, and -$228406.0 in Q3 2024.